Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload.

Date publication

mai 2018

Journal

European journal of haematology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AME Shanti

Tous les auteurs :
Rose C, Lenoir C, Gyan E, Hacini M, Amé S, Corront B, Beyne-Rauzy O, Adiko D, Loppinet E, Ali-Ammar N, Laribi K, Wattel E, Dreyfus F, Roué CS, Cheze S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29719933

Résumé

To assess the reduction of transfusions rate in transfusion-dependent patients with low-risk myelodysplastic syndrome (MDS) with iron overload treated with deferasirox.

Mots clés

deferasirox, iron chelation, myelodysplastic syndrome, transfusion

Référence

Eur. J. Haematol.. 2018 May 2;: